ImmuneOncia Therapeutics, Inc. (KOSDAQ:424870)

Market Cap	825.46B
Revenue (ttm)	715.75M
Net Income (ttm)	-20.52B
Shares Out	74.17M
EPS (ttm)	-306.31
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,105,213
Average Volume	13,808,917
Open	11,750
Previous Close	11,830
Day's Range	10,810 - 11,940
52-Week Range	4,455 - 12,100
Beta	n/a
RSI	69.11
Earnings Date	n/a

About ImmuneOncia Therapeutics

ImmuneOncia Therapeutics, Inc., an immuno-oncology-centric biopharmaceutical company, develops immuno-oncology drugs for the treatment of cancer. It develops IMC-001, a human monoclonal antibody of the IgG1 type that targets PD-L1 an immunotherapy for cancer, which is in Phase II clinical trial for the treatment of NK/T cell lymphoma and solid cancer patients with high tumor mutation burden; and IMC-002, a human monoclonal antibody of the IgG4 type targeting human CD47, which is in Phase I a clinical trial for the treatment of solid cancers, su...

• Industry: Pharmaceutical Preparations
• Founded: 2016
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 424870